<p>阿斯利康的英国董事长威胁称，除非政府在国家医疗服务体系（NHS）药品定价争议上让步，否则将停止对英国的投资。</p>
<p>肖恩·格雷迪警告称，英国面临从全球吸引力目的地名单中消失的危险，除非其将 “糟糕的” 药品定价制度带入 21 世纪。</p>
<p>在保守党大会上，格雷迪表示，英国在采用创新方面 “落后”，导致患者无法获得前沿药物治疗。</p>
<p>他指责政府对新项目缺乏支持，以及对品牌药物支出设定上限的协议，使未来投资面临风险。</p>
<p>阿斯利康上个月宣布，计划暂停对其剑桥研究中心的 2 亿英镑升级。该公司此前因工党削减该项目的资金，已取消了对其利物浦疫苗生产厂的 4.5 亿英镑扩建计划。</p>
<p>格雷迪表示：“我们（英国）在药物投资方面未能跟上步伐。”</p>
<p>当被问及公司需要什么条件才能继续剑桥投资时，他表示：“除非商业环境发生变化，否则英国不会在名单上。”</p>
<p>格雷迪补充说，随着与政府的谈判继续，公司将 “重新审视和反思” 其剑桥计划。</p>
<p>卫生部长韦斯·斯特里廷在夏季与制药公司谈判后未能达成新的药品定价协议而离开。据信，谈判仍在进行中，由科学部长瓦兰斯勋爵主导。</p>
<p>虽然格雷迪表示阿斯利康仍然是英国的重要投资者，但他指出，由于国家健康与护理卓越研究所（Nice）使用的过时系统，导致公司错失了重要投资，该系统自 1999 年以来基本保持不变。</p>
<p>这一系统通过一个公式来确定药物的有效性，即为一个人提供一年健康生活的成本。</p>
<p>“阈值已经 25 年没有改变，这真是令人震惊，” 格雷迪说。</p>
<p>他补充说，与英国不同，爱尔兰和新加坡等国家为公司提供了显著的补贴或税收减免以吸引投资。他还将英国与美国进行比较，后者在 7 月宣布到 2030 年将投资 500 亿英镑。</p>
<p>“这是一个竞争激烈的全球市场，” 格雷迪说。“我们在美国宣布了 500 亿英镑的投资。我们在伦敦的办公室会见了弗吉尼亚州州长，33 天后宣布了这项 500 亿英镑的投资。我们需要考虑这种速度，以及什么才是真正的礼宾服务。”</p>
<p>在同一小组发言的哈林顿勋爵——他曾在上届保守党政府下进行投资审查——表示，缺乏整体思维也阻碍了增长。</p>
<p>他说：“卫生部有一间充满公务员的房间，他们的工作基本上是对制药公司施加压力，以尽可能降低政府支付的药品价格。他们不被允许全面考虑这些决定对国家投资的影响，而公司显然会考虑。”</p>
<p>阿斯利康作为英国最大的上市公司，其决定意味着 2024 年宣布的 6.5 亿英镑投资计划面临搁置的风险。</p>
<p>卫生部在今年年初在美国总统唐纳德·特朗普的压力下启动了对所谓 NHS 回扣的审查，特朗普要求制药公司降低美国的药品价格——美国的药品价格远高于英国和欧洲。</p>
<p>一项自愿协议目前对 NHS 在品牌药物上的支出设定了上限，以努力控制成本。</p>
<p>总账单每年允许上涨一定比例。如果 NHS 在品牌药物上的支出超过预期，它可以通过药品回扣收回部分资金。</p>
<p>政府在去年年底意外将 2025 年新药的回扣率提高到近 23%。</p>
<p>制药公司高管警告称，该计划正在阻碍前沿药物在英国的推出。他们已敦促英国将回扣率降低到个位数，这是欧洲其他地方的水平。</p>
<p>政府已被联系以发表评论。</p>

阿斯利康

<p>阿斯利康在英国的董事长肖恩·格雷迪（Shaun Grady）威胁称，除非政府解决国家医疗服务体系（NHS）药品定价争端，否则将停止在英国的投资。他警告称，由于过时的药品定价政策，英国面临失去作为全球投资目的地的吸引力的风险</p>

<p>AstraZeneca’s UK chairman has threatened to halt investment in Britain unless the Government backs down over an NHS drug pricing row.</p>
<div class="lb-trans"><p>阿斯利康的英国董事长威胁称，除非政府在国家医疗服务体系（NHS）药品定价争议上让步，否则将停止对英国的投资。</p>
</div><p>Shaun Grady warned that Britain was in danger of disappearing from a list of attractive global destinations unless it brings its “appalling” drug pricing regime into the 21st century.</p>
<div class="lb-trans"><p>肖恩·格雷迪警告称，英国面临从全球吸引力目的地名单中消失的危险，除非其将 “糟糕的” 药品定价制度带入 21 世纪。</p>
</div><p>Speaking at the Conservative Party conference, Mr Grady said the UK “fell down” on adopting innovation with patients being denied cutting-edge drug treatments as a result.</p>
<div class="lb-trans"><p>在保守党大会上，格雷迪表示，英国在采用创新方面 “落后”，导致患者无法获得前沿药物治疗。</p>
</div><p>He blamed a lack of government support for new projects and an agreement that places a cap on how much the NHS spends on branded medicines for putting future investment at risk.</p>
<div class="lb-trans"><p>他指责政府对新项目缺乏支持，以及对品牌药物支出设定上限的协议，使未来投资面临风险。</p>
</div><p>AstraZeneca announced last month that it was putting on hold a planned £200m upgrade of its Cambridge research site. The company had earlier axed a £450m expansion of its vaccine manufacturing plant in Liverpool after Labour cut funding for the project.</p>
<div class="lb-trans"><p>阿斯利康上个月宣布，计划暂停对其剑桥研究中心的 2 亿英镑升级。该公司此前因工党削减该项目的资金，已取消了对其利物浦疫苗生产厂的 4.5 亿英镑扩建计划。</p>
</div><p>Mr Grady said: “We’ve [the UK] failed to keep pace on medicine investment over the years.”</p>
<div class="lb-trans"><p>格雷迪表示：“我们（英国）在药物投资方面未能跟上步伐。”</p>
</div><p>Asked what it would take for the company to go ahead with the Cambridge investment, he said: “Unless the commercial environment changes, the UK is not going to be on the list.”</p>
<div class="lb-trans"><p>当被问及公司需要什么条件才能继续剑桥投资时，他表示：“除非商业环境发生变化，否则英国不会在名单上。”</p>
</div><p>Mr Grady added that the company would “revisit and reflect” on its Cambridge plans as talks with the Government continue.</p>
<div class="lb-trans"><p>格雷迪补充说，随着与政府的谈判继续，公司将 “重新审视和反思” 其剑桥计划。</p>
</div><p>Wes Streeting, the Health Secretary, walked away from talks with drugmakers this summer after failing to strike a new pricing deal on medicines supplied to the NHS. It is understood that talks are still ongoing, led by Lord Vallance, the science minister.</p>
<div class="lb-trans"><p>卫生部长韦斯·斯特里廷在夏季与制药公司谈判后未能达成新的药品定价协议而离开。据信，谈判仍在进行中，由科学部长瓦兰斯勋爵主导。</p>
</div><p>While Mr Grady said AstraZeneca remained a significant investor in the UK, he said it was missing out on vital investment because of an antiquated system used by the National Institute for Health and Care Excellence (Nice) to determine which treatments are available on the NHS that has largely remained the same since 1999.</p>
<div class="lb-trans"><p>虽然格雷迪表示阿斯利康仍然是英国的重要投资者，但他指出，由于国家健康与护理卓越研究所（Nice）使用的过时系统，导致公司错失了重要投资，该系统自 1999 年以来基本保持不变。</p>
</div><p>This is determined by a formula which looks at drug effectiveness in terms of how much it would cost to give a person a year of healthy life.</p>
<div class="lb-trans"><p>这一系统通过一个公式来确定药物的有效性，即为一个人提供一年健康生活的成本。</p>
</div><p>“The thresholds have not been changed for 25 years, which is pretty appalling,” said Mr Grady.</p>
<div class="lb-trans"><p>“阈值已经 25 年没有改变，这真是令人震惊，” 格雷迪说。</p>
</div><p>He added that, unlike the UK, countries including Ireland and Singapore were offering companies significant subsidies or tax breaks to invest there. He also compared Britain with the US, where the company announced in July it would invest £50bn by 2030.</p>
<div class="lb-trans"><p>他补充说，与英国不同，爱尔兰和新加坡等国家为公司提供了显著的补贴或税收减免以吸引投资。他还将英国与美国进行比较，后者在 7 月宣布到 2030 年将投资 500 亿英镑。</p>
</div><p>“This is a competitive global pitch,” said Mr Grady. “We announced a £50bn investment in the US. We met the governor of Virginia in our offices in London, we announced that £50bn investment 33 days later. We need to think about that speed and what truly is a concierge service.”</p>
<div class="lb-trans"><p>“这是一个竞争激烈的全球市场，” 格雷迪说。“我们在美国宣布了 500 亿英镑的投资。我们在伦敦的办公室会见了弗吉尼亚州州长，33 天后宣布了这项 500 亿英镑的投资。我们需要考虑这种速度，以及什么才是真正的礼宾服务。”</p>
</div><p>Speaking on the same panel, Lord Harrington – who led a review on investment under the last Tory government – said a lack of joined-up thinking was also stymieing growth.</p>
<div class="lb-trans"><p>在同一小组发言的哈林顿勋爵——他曾在上届保守党政府下进行投资审查——表示，缺乏整体思维也阻碍了增长。</p>
</div><p>He said: “There’s a room full of civil servants in the Department of Health whose job it is to basically kick the c--- out of pharmaceutical companies to get the price that the government pays for drugs as low as possible. They are not allowed to consider holistically the effect of those decisions on investment in a country, whereas a company clearly does.”</p>
<div class="lb-trans"><p>他说：“卫生部有一间充满公务员的房间，他们的工作基本上是对制药公司施加压力，以尽可能降低政府支付的药品价格。他们不被允许全面考虑这些决定对国家投资的影响，而公司显然会考虑。”</p>
</div><p>The decision by AstraZeneca, the UK’s largest listed company, means all of its £650m investment package announced in 2024 risks being shelved.</p>
<div class="lb-trans"><p>阿斯利康作为英国最大的上市公司，其决定意味着 2024 年宣布的 6.5 亿英镑投资计划面临搁置的风险。</p>
</div><p>The Department of Health launched a review of so-called NHS rebates earlier this year under pressure from Donald Trump, the US president, who has demanded that pharmaceutical companies lower their drug prices in the US – where they are much higher than the UK and Europe.</p>
<div class="lb-trans"><p>卫生部在今年年初在美国总统唐纳德·特朗普的压力下启动了对所谓 NHS 回扣的审查，特朗普要求制药公司降低美国的药品价格——美国的药品价格远高于英国和欧洲。</p>
</div><p>A voluntary agreement currently places a cap on how much the NHS spends on branded medicines as part of efforts to keep costs down.</p>
<div class="lb-trans"><p>一项自愿协议目前对 NHS 在品牌药物上的支出设定了上限，以努力控制成本。</p>
</div><p>The total bill is allowed to rise by a certain percentage each year. If the NHS spends more than expected on branded medicines, it is able to claw some of that money back in rebates on drugs.</p>
<div class="lb-trans"><p>总账单每年允许上涨一定比例。如果 NHS 在品牌药物上的支出超过预期，它可以通过药品回扣收回部分资金。</p>
</div><p>The Government raised the rate unexpectedly to almost 23pc for 2025 for newer medicines at the end of last year.</p>
<div class="lb-trans"><p>政府在去年年底意外将 2025 年新药的回扣率提高到近 23%。</p>
</div><p>Pharmaceutical bosses have warned the scheme is preventing the launch of cutting-edge medicines in the UK. They have pressed the UK to cut the rate of rebates into single digits, a level seen elsewhere in Europe.</p>
<div class="lb-trans"><p>制药公司高管警告称，该计划正在阻碍前沿药物在英国的推出。他们已敦促英国将回扣率降低到个位数，这是欧洲其他地方的水平。</p>
</div><p>The Government has been contacted for comment.</p>
<div class="lb-trans"><p>政府已被联系以发表评论。</p>
</div>

阿斯利康威胁停止在英国的投资